Research programme: DNA repair inhibitors - Ignyta/Cancer Research TechnologyAlternative Names: RXDX-108; TEV-44229
Latest Information Update: 29 Jun 2016
At a glance
- Originator Cancer Research Technology; Teva Pharmaceutical Industries
- Developer Cancer Research Technology; Ignyta
- Class Small molecules
- Mechanism of Action DNA repair inhibitors; Protein kinase C inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer